Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease

Movement Disorders

Volumn 27, Issue 3, 2012, Pages 439-442

  Cubo, Esther ^a   González, Miguel ^b   del Puerto, Inés ^b   de Yébenes, Justo Garcia ^c   Arconada, Olga Fernández ^a   Gabriel y Galán, José María Trejo ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Clinical trials; Huntington's disease; Movement disorders; Placebo

Indexed keywords

PLACEBO;

ADULT; ARTICLE; BEHAVIOR; COGNITION; DEPRESSION; FEMALE; FUNCTIONAL STATUS; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PLACEBO EFFECT; PRIORITY JOURNAL;

ADULT; AGED; CLINICAL TRIALS AS TOPIC; DATABASES, BIBLIOGRAPHIC; DISABILITY EVALUATION; FEMALE; HUMANS; HUNTINGTON DISEASE; INTERNATIONALITY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLACEBO EFFECT; PLACEBOS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84858293928     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24062     Document Type: Article

References (22)

1. de la Fuente-Fernández R, Ruth TJ, Sossi V, et al. Expectation and dopamine release in Parkinson's disease: mechanisms of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-1166.
2. Fricchione G, Stefano GB. Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries. Med Sci Monit 2005; 11: MS54-MS65.
3. de la Fuente-Fernández R, Schulzer M, Stoessl AJ. Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry 2004; 56: 67-71.
4. de la Fuente-Fernández R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders. Lancet Neurol 2002; 1: 85-91.
5. Landwehrmeyer GB, Dubois B, de Yébenes JG, et al; European Huntington's Disease Initiative Study Group. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007; 62: 262-272.
6. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136-142.
7. Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008; 23: 700-707.
8. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology 2000; 54: 710-714.
9. Goetz CG, Leurgans S, Raman R; The Parkinson StudyGroup. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UDPRS in early Parkinson's disease. Mov Disord 2002; 17: 283-288.
10. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
11. Guy W. CGI: Clinical Global Impressions. In: ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976: 217-222.
12. Yoav B, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Soc Series B Stat Methodol 1995; 57: 289-300.
13. R Foundation for Statistical Computing. The R Project for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011. Available at: Accessed November 20, 2011.
14. Moreno JL, de Yebenes JG. The impact of an intense religious experience on motor symptoms in Huntington's disease. Mov Disord 2009; 24: 473-474.
15. Goldberg HL, Finnerty RJ. Trazodone in the treatment of neurotic depression. J Clin Psychiatry 1980; 41: 430-434.
16. Kiev A, Okerson L. Comparison of the therapeutic efficacy of amoxapine with that of imipramine. Clin Trials J 1979; 16: 68-72.
17. Rickels K, Case WG, Werblowsky J, Casanalosi I, Schless A, Weise CC. Amoxapine and imipramine in the treatment of depressed outpatients: a controlled study. Am J Psychiatry 1981; 138: 20-24.
18. Casper RC, Tollefson GD, Nilsson ME. No gender differences in placebo responses of patients with major depressive disorder. Biol Psychiatry 2001; 49: 158-160.
19. Vaccarino AL, Anderson K, Borowsky B, et al.; PREDICT-HD and REGISTRY Investigators Coordinators. An item response analysis of the motor and behavioral subscales of the Unified Huntington's Disease Rating Scale in Huntington disease gene expansion carriers. Mov Disord 2011; 26: 877-884.
20. Louis ED, Anderson KE, Moskowitz C, Thorne DZ, Marder K. Dystonia-predominant adult-onset Huntington disease: association between motor phenotype and age at onset in adults. Arch Neurol 2000; 57: 1326-1330.
21. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 2004; 256: 91-100.
22. Siesling S, van Vugt JPP, Zwinderman KAH, Kieburtz K, Roos RAC. Unified Huntington's Disease Rating Scale: a follow up. Mov Disord 1998; 13: 915-919.